
Urokinase plasminogen activator receptor (uPAR) is a key component in proteolysis and extracellular matrix degradation during cancer invasion and metastasis. uPAR overexpression is an important biomarker for aggressiveness in several solid tumors and provides independent clinical information. A recent major breakthrough was obtained with human translation of uPAR PET using 68Ga-NOTA-AE105. Clinical results are encouraging and several large-scale clinical trials are now ongoing. This review focuses on uPAR PET with 68Ga-NOTA-AE105 as a new broadly applicable diagnostic and prognostic imaging biomarker in cancer.
Prostate cancer, Molecular imaging, Gallium Radioisotopes, Prognostication, Theranostics, Ligands, Invasiveness, Receptors, Urokinase Plasminogen Activator, Breast cancer, PET, Oncology, Neoplasms, Positron-Emission Tomography, Humans, Radiopharmaceuticals, Radionuclide Imaging, Tomography, X-Ray Computed
Prostate cancer, Molecular imaging, Gallium Radioisotopes, Prognostication, Theranostics, Ligands, Invasiveness, Receptors, Urokinase Plasminogen Activator, Breast cancer, PET, Oncology, Neoplasms, Positron-Emission Tomography, Humans, Radiopharmaceuticals, Radionuclide Imaging, Tomography, X-Ray Computed
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 10 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
